Table 2.
Comparison of clinical and laboratory characteristics of SMZL patients stratified by type of primary treatment
| Variable | Grup A Splenectomy (N=21) |
Grup B Rituximab (N=8) |
Grup C Chemotherapy (N=9) |
p-value |
|---|---|---|---|---|
| Age (median, range) | 61 (41-76) | 54 (33-71) | 65 (28-76) | 0.194 |
| Β2-microglobulin (median) | 2.95 mg/dl | 4.15 mg/dl | 4.75 mg/dl | 0.048 |
| LDH (median) | 388 U/L | 452 U/L | 535 U/L | 0.050 |
| Albumin (median) | 4.20 g/dl | 3.65 g/dl | 3.80 g/dl | 0.005 |
| Hemoglobin (median) | 110 g/L | 91 g/L | 100 g/L | 0.340 |
| Platelets (median) | 118 x 109/L | 115 x 109/L | 112 x 109/L | 0.213 |
| Comorbities ≥ 2 | 14.3 % | 100 % | 44.4 % | 0.00024 |
| ECOG ≥ 2 | 9.5 % | 75 % | 55.5 % | 0.050 |
| Arcaine int/high-risk | 33.3 % | 62.5 % | 44.4 % | 0.116 |
| SMZL-WG int/high-risk | 76.2 % | 100 % | 100 % | 0.030 |
B2-microglobulin: A x B p=0.047, A x C p=0.038, B x C p=0.274
LDH: A x B p=0.050, A x C p=0.023, B x C p=0.170
Albumin: A x B p= 0.030, A x C p=0.048, B x C p=0.176
Comorbities: A x B p= 0.0001, A x C p=0.025, B x C p=0.00034
ECOG: A x B p= 0.002, A x C p= 0.037, B x C p=0.164
SMZL/WG: A x B p=0.023, A x C p=0.023, B x C p=0.547